Taken together, these results suggest that bromodomain inhibitors decrease ASCL1 expression and downregulate its downstream target gene, IGFBP5. The release of this inhibitory loop results in enhanced IGF-1R signaling and sensitizes these ASCL1High SCLC cells to IGF-1R inhibitors. The gene discussed is IGF1R; the disease is small cell lung carcinoma.